1. Pink Sheet

Making Imodium Rx-Only No Help On Curbing Opioid Abuse – CHPA

 
• By Eileen Francis

Making OTC diarrhea remedy loperamide Rx-only is unlikely to reduce abuse and would cause problems for millions of US consumers who depend on the product, says the Consumer Healthcare Products Association, responding to a petition advocating the change.

Making all loperamide-containing diarrhea remedies Rx-only is unlikely to reduce abuse and misuse of the drug but would unfairly limit access for millions of consumers who use OTC versions safely, says the Consumer Healthcare Products Association.

In a Sept. 5 letter to FDA, Jay Sirois, CHPA's senior director of regulatory and scientific affairs, suggests...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.